Proteolytic and lipolytic enzyme which is derived from mammalian pancreas that has protease, lipase and amylase activity. Indicated for treatment of cystic fibrosis and chronic pancreatitis.
At latest update no published data on excretion into breast milk was found.
Its high molecular weight and poor intestinal absorption make it highly unlikely a significant passage to the milk.
A low oral bioavailability hinders the passage into infant plasma from ingested milk.
It is a medication used in children and young infants.
We do not have alternatives for Pancreatin since it is relatively safe.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
- παγκρεατίνη (Greek)
- πανκρελιπάση (Greek)
- Панкрелипаза (Cyrillic)
- パンクレアチン (Japanese)
- パンクレリパーゼ (Japanese)
Drug trade names
- Espaven Enzimatico™
- Espaven Enzimatico™ (Mexico)
- Fermetone Composto™
- BGP. Pancreatine. Product Monograph. 2014 Full text (in our servers)
- AEMPS. Pancreatina. Ficha técnica. 2012 Full text (in our servers)
- Colombo C, Fredella C, Russo MC, Faelli N, Motta V, Valmarana L, Longo L, D'Orazio C. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas. 2009Abstract